A Spatially Constrained Fibroblast–Myeloid Program Associates With Immune Exclusion and Poor Prognosis in Lung Adenocarcinoma
Human Mutation · 2026-01 · 2026 (1)
DOI: 10.1155/humu/8218916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Mutation, online erschienen am 26.05.2026. Verfasst von Yujun Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hunan Provincial Key Laboratory for Special Pathogens Preventio…. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Adenocarcinoma of Lung, Lung Neoplasms, Myeloid Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hunan University.
Abstract (Originalsprache)
Background
Although immune checkpoint blockade (ICB) therapy has improved clinical outcomes for some patients with lung adenocarcinoma (LUAD), only a subset of cases can achieve durable benefits, and primary resistance is often associated with an immune‐excluded tumor microenvironment (TME). Existing studies indicate that cancer‐associated fibroblasts (CAFs) are increasingly recognized as important participants in extracellular matrix (ECM) remodeling and stroma‐immune crosstalk. However, in LUAD, it is still unclear which CAFs‐related programs are involved in immune exclusion, particularly in relation to their spatial interactions with myeloid cell states.
Methods
We integrated eight publicly available LUAD single‐cell RNA‐seq cohorts (164 samples; 471,501 cells) using Harmony and annotated major lineages and stromal subsets. CAFs were reclustered to resolve subtype heterogeneity, followed by pathway activity scoring, weighted gene coexpression network analysis (WGCNA), pseudotime trajectory inference (Slingshot), and regulon analysis. Bulk TCGA‐LUAD data were used for immune‐exclusion correlation and survival analyses. Spatial transcriptomics was applied for in situ validation, and ligand–receptor analysis together with NicheNet was used to prioritize CAFs‐derived signaling interactions and downstream targets.
Results
The integrated atlas identified 10 major cell lineages and revealed tumor‐associated expansion of stromal and myeloid compartments. We further resolved six CAFs subtypes with distinct molecular and functional features. Tumor‐enriched CAFs subsets showed stronger activation of ECM remodeling, focal adhesion, TGF‐ β signaling, hypoxia‐related pathways, and inflammatory programs. Bulk‐level analyses in TCGA‐LUAD demonstrated that CAFs‐related signatures were associated with a T‐cell exclusion index and increased expression of the immune checkpoint–related molecule CD276 (B7‐H3). Spatial transcriptomic mapping further showed that selected CAFs signatures were enriched in hypoxic, nonepithelial regions and colocalized with myeloid‐associated signals, supporting the presence of a spatially constrained fibro‐myeloid niche. Cell–cell communication analysis revealed extensive ligand–receptor interactions between CAFs subtypes and myeloid populations, whereas survival and immunotherapy cohort analyses showed that specific CAFs‐related programs were associated with worse clinical outcomes and less favorable treatment responses.
Conclusions
Multicohort single‐cell integration and spatial validation define a CAFs‐centered, immune‐excluded niche in LUAD characterized by coordinated stromal and myeloid programs. These findings improve current understanding of CAFs heterogeneity and fibroblast–myeloid coupling in LUAD and provide a framework for future strategies aimed at targeting stromal barriers and remodeling the immune microenvironment to enhance ICB responsiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Hengyang, Hunan, China, usc.edu.cn.
- Institute of Translational Medicine, School of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang, Hunan, China, usc.edu.cn.
- Department of Clinical Laboratory, Jining First People's Hospital, Jining, Shandong, China.
ORCID-Profile: Yujun Zhou, Pengpeng Sun, Nan Ding
Förderung
- National Natural Science Foundation of China
- Hunan University
Zitieren
APA
Zhou, Y., Ren, X., Li, R., Chen, S., Wei, B., Shen, Y., Wang, X., Xia, Y., Cao, S., Sun, P., & Ding, N. (2026). A Spatially Constrained Fibroblast–Myeloid Program Associates With Immune Exclusion and Poor Prognosis in Lung Adenocarcinoma. Human Mutation, 2026(1). https://doi.org/10.1155/humu/8218916
Vancouver
Zhou Y, Ren X, Li R, Chen S, Wei B, Shen Y, et al. A Spatially Constrained Fibroblast–Myeloid Program Associates With Immune Exclusion and Poor Prognosis in Lung Adenocarcinoma. Human Mutation. 2026;2026(1). doi:10.1155/humu/8218916
BibTeX
@article{Zhou2026,
author = {Zhou, Yujun and Ren, Xinyang and Li, Rongxin and Chen, Sihan and Wei, Bo and Shen, Yi and Wang, Xiang and Xia, Yuzhen and Cao, Siyu and Sun, Pengpeng and Ding, Nan},
title = {A Spatially Constrained Fibroblast–Myeloid Program Associates With Immune Exclusion and Poor Prognosis in Lung Adenocarcinoma},
journal = {Human Mutation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/humu/8218916}
}
EUVIMED